 PRINCETON, N.J., Oct. 12, 2021 PRNewswire -- Soligenix, Inc. Nasdaq: SNGX Soligenix or the Company, a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today their poster abstract was selected as a top abstract winner and has been accepted for display and presentation at the 2021 National Organization for Rare Disorders NORD Rare Diseases and Orphan Products Breakthrough Summit to be held virtually on October 18-19, 2021. 